Evidence map›Paper›PMID 41716048›Full record

ArticleBioscience reports2026

Observation of aldicarb hydrolysis by a cocaine hydrolase.

Johnathan E LeSaint, Daniel J Peter, Huimei Wei, Shawn Park, Chang-Guo Zhan, Fang Zheng

Abstract read
In one paragraph

Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Johnathan E LeSaint *Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, U.S.A.
Daniel J Peter *Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, U.S.A.
Huimei Wei *Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, U.S.A.
Shawn ParkDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, U.S.A.
Chang-Guo ZhanMolecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, U.S.A.ORCID 0000-0002-4128-7269
Fang ZhengMolecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536, U.S.A.ORCID 0000-0001-8571-3744

Funding

Development of a Long-acting Enzyme Therapy for Treatment of Cocaine AbuseU01DA051079 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2020 to 2022
$11.8M
Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatmentR01DA035552 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2013 to 2015
$3.4M
Redesign of Butyrylcholinesterase for Cocaine MetabolismR01DA013930 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2003 to 2010
$2.4M
Ghrelin Deacylase as a Treatment for Opioid Polysubstance AbuseR01DA056646 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO, ZHENG, FANG · 2022 to 2025
$2.2M
Development of a Cocaine-Metabolizing Enzyme for Drug Overdose TreatmentR01DA032910 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2012 to 2015
$1.8M
Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoningUH3NS134920 · NINDS · UNIVERSITY OF KENTUCKY · PI CHANG-GUO ZHAN, Fang Zheng · 2025 to 2026
$1.3M
Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoningUG3NS134920 · NINDS · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO, ZHENG, FANG · 2023 to 2024
$1.1M
Validation of ghrelin hydrolysis as an effective approach to treatment of substance use disordersU18DA052319 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHENG, FANG · 2020 to 2020
$230k
NIH HHS R01 DA013930NIH HHS R01 DA032910NIH HHS R01 DA035552NIH HHS R01 DA056646NIH HHS U01 DA051079NIH HHS U18 DA052319NIH HHS UG3/UH3 NS134920NIH HHS UG3/UH3 NS134920, U01 DA051079, UH2/UH3 DA041115, R01 DA056646, U18 DA052319, R01 DA035552, R01 DA032910, and R01 DA013930NIH HHS UH2/UH3 DA041115NINDS NIH HHS UG3 NS134920NINDS NIH HHS UH3 NS134920
6 · The paper itself

Abstract

Aldicarb is a carbamate pesticide used for pest control in agriculture. As a fast-acting acetylcholinesterase inhibitor, aldicarb interferes with the nervous system by preventing the breakdown of acetylcholine. Aldicarb could be used as a chemical-warfare agent to cause mass casualty incidents. There is no specific FDA-approved medication for aldicarb detoxification. Our previous study revealed that an Fc-fused butyrylcholinesterase (BChE) mutant, known as CocH3-Fc(M3), can be inhibited rapidly by aldicarb and that the aldicarb-inhibited enzyme CocH3-Fc(M3) can be reactivated spontaneously, suggesting that CocH3-Fc(M3) may hydrolyze aldicarb. However, the suggested CocH3-Fc(M3)-catalyzed hydrolysis of aldicarb was not confirmed experimentally in the previous study. In the present study, by developing an LC-MS/MS method to detect and quantify aldicarb and aldicarb oxime concentrations, we were able to directly observe the CocH3-Fc(M3)-catalyzed aldicarb hydrolysis for the first time, confirming that CocH3-Fc(M3) indeed has the desirable catalytic activity for aldicarb hydrolysis and may be considered as the first aldicarb hydrolase identified so far. Further, we carried out Michaelis-Menten kinetic analysis on the CocH3-Fc(M3)-catalyzed aldicarb hydrolysis and determined the catalytic parameters (kcat = 0.060 min-1, KM = 2.5 μM, and kcat/KM = 2.4 × 104 min-1 M-1) at 37°C. The obtained kinetic parameters at 37°C will be valuable for further in vivo studies and translational research using CocH3-Fc(M3) and for designing more potent enzymes to hydrolyze aldicarb in the future. Additionally, the LC-MS/MS method developed in this study may serve as a valuable tool to accurately detect aldicarb and its reaction products in future food and environmental safety control efforts and aldicarb-related toxicology studies.

Indexed as

AldicarbButyrylcholinesteraseCarboxylic Ester HydrolasesCholinesterase InhibitorsHumansHydrolysisKineticsRecombinant ProteinsTandem Mass SpectrometryAldicarbButyrylcholinesteraseCarboxylic Ester HydrolasesCholinesterase Inhibitorscocaine hydrolaseRecombinant ProteinsCarbamatecholinergic warfarecocaine hydrolaseesterasehydrolysispesticide

Identifiers

PMID41716048
PMCPMC13136561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.